Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer

The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib (Ibrance, Pfizer) was approved in combination with trastuzumab (Herceptin, Genentech), with or without pertuzumab (Perjeta, Genetech), and endocrine therapy as maintenance treatment for adults with HR-positive,